论文部分内容阅读
目的观察贝那普利联合罗格列酮治疗高血压伴胰岛素抵抗(insulin resistance,IR)患者的降压疗效和对IR的影响。方法将86例高血压伴IR患者随机分为治疗组和对照组(各43例),前者给予贝那普利和罗格列酮治疗,后者单予贝那普利治疗,疗程均为6个月。观察2组治疗前后血糖、胰岛素敏感指数、血压的变化及不良反应。结果治疗组服药后空腹血糖、空腹胰岛素及餐后2h血糖均下降,胰岛素敏感指数升高,与对照组比较差异均有统计学意义(P<0.05orP<0.01)。2组服药后收缩压与舒张压均下降,但治疗组收缩压下降幅度较对照组大。2组在治疗期间均未出现明显不良反应。结论采用贝那普利联合罗格列酮治疗方案治疗高血压伴IR患者,可明显改善患者的IR状况,有利于提高降压疗效。
Objective To observe the antihypertensive efficacy and the effect of benazepril on rosiglitazone in patients with hypertension and insulin resistance (IR). Methods Eighty-six patients with hypertension and IR were randomly divided into treatment group and control group (43 cases each). The former was treated with benazepril and rosiglitazone, the latter with benazepril alone. The course of treatment was 6 month. The changes of blood glucose, insulin sensitivity index, blood pressure and adverse reactions in two groups before and after treatment were observed. Results After treatment, fasting blood glucose, fasting insulin and postprandial 2h blood glucose were decreased and insulin sensitivity index was increased in the treatment group compared with the control group (P <0.05orP <0.01). Systolic blood pressure and diastolic blood pressure decreased after treatment in both groups, but the decrease of systolic blood pressure in the treatment group was larger than that in the control group. No significant adverse reactions occurred in the two groups during the treatment. Conclusion The combination of benazepril and rosiglitazone in the treatment of patients with hypertension and IR can significantly improve the IR status of patients and improve the antihypertensive effect.